MATCAP1
gene geneOn this page
Also known as LOC653319TMCP1
Summary
MATCAP1 (microtubule associated tyrosine carboxypeptidase 1, HGNC:34408) is a protein-coding gene on chromosome 16q22.1, encoding Microtubule-associated tyrosine carboxypeptidase 1 (Q68EN5). Tyrosine carboxypeptidase that removes the C-terminal tyrosine residue of alpha-tubulin, thereby regulating microtubule dynamics and function.
Enables tubulin-tyrosine carboxypeptidase activity. Predicted to be involved in brain development. Is active in microtubule.
Source: NCBI Gene 653319 — automated summary from GO annotations (Alliance of Genome Resources).
At a glance
- GWAS associations: 2
- Clinical variants (ClinVar): 81 total
- GTEx eGene: eQTL in 17 tissues, sQTL in 7 (q < 0.05)
- Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.97 (unconstrained)
- MANE Select transcript:
NM_001040715 - Notable: 81 clinical variants but no curated precision-oncology (CIViC) evidence yet
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:34408 |
| Approved symbol | MATCAP1 |
| Name | microtubule associated tyrosine carboxypeptidase 1 |
| Location | 16q22.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | LOC653319, TMCP1 |
| Ensembl gene | ENSG00000196123 |
| Ensembl biotype | protein_coding |
| OMIM | 619978 |
| Entrez | 653319 |
Gene structure
Transcript identifiers
Ensembl transcripts: 19 — 9 protein_coding, 5 protein_coding_CDS_not_defined, 3 retained_intron, 2 nonsense_mediated_decay
MANE Select: ENST00000563902
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3, TSL 2: 2, TSL 3: 1, TSL 4: 2, TSL 5: 4
ENST00000563902, ENST00000290881, ENST00000561621, ENST00000561679, ENST00000562514, ENST00000563831, ENST00000563918, ENST00000564423, ENST00000564835, ENST00000568165, ENST00000568563, ENST00000570009, ENST00000886314, ENST00000886315, ENST00000944219, ENST00000944220, ENST00001074660, ENST00001074661, ENST00001133323
RefSeq mRNA: 8 — MANE Select: NM_001040715
NM_001040715, NM_001369680, NM_001369681, NM_001369682, NM_001369684, NM_001369685, NM_001369686, NM_001369687
CCDS: CCDS42177, CCDS92174
Canonical transcript exons
ENST00000563902 — 7 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001674068 | 67180041 | 67180666 |
| ENSE00002600108 | 67175599 | 67176975 |
| ENSE00002625662 | 67183262 | 67183963 |
| ENSE00003473008 | 67179815 | 67179958 |
| ENSE00003577066 | 67178199 | 67178504 |
| ENSE00003648148 | 67179430 | 67179562 |
| ENSE00003702588 | 67178010 | 67178107 |
Expression profiles
Bgee: expression breadth ubiquitous, 196 present calls, max score 98.60.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.6843 / max 868.3864, expressed in 1789 samples.
Highest expression (Bgee): hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex, cerebellum, cortical plate.
Genetic regulation across tissues (GTEx eQTL / sQTL)
MATCAP1 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 17 tissues and its splicing (sQTL) in 7 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
showing 20 of 24 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Brain Cerebellar Hemisphere | eqtl | 2.5e-25 | +0.63 | 16:67178909:A:AC |
| Brain Cerebellum | eqtl | 1.9e-22 | +0.68 | 16:67178909:A:AC |
| Brain Cortex | eqtl | 1.4e-11 | +0.48 | 16:67185204:G:C |
| Brain Frontal Cortex BA9 | eqtl | 2.6e-10 | +0.43 | 16:67178909:A:AC |
| Adipose Visceral Omentum | sqtl | 1.6e-05 | +0.56 | 16:67089338:C:G |
| Lung | sqtl | 4.7e-05 | +0.69 | 16:67178129:GAGCCCCGCCCCTCGCCCGA:G |
| Skin Not Sun Exposed Suprapubic | eqtl | 1.0e-04 | +0.30 | 16:67664019:C:T |
| Skin Sun Exposed Lower leg | eqtl | 3.3e-04 | +0.33 | 16:67290232:C:T |
| Esophagus Mucosa | sqtl | 4.8e-04 | +0.55 | 16:67184472:T:G |
| Nerve Tibial | eqtl | 7.7e-04 | -0.16 | 16:67220516:A:G |
| Brain Cerebellum | sqtl | 9.7e-04 | -0.65 | 16:67209542:T:C |
| Brain Hippocampus | eqtl | 3.8e-03 | +0.51 | 16:67480240:G:A |
| Adipose Subcutaneous | eqtl | 4.1e-03 | +0.37 | 16:66608081:A:C |
| Muscle Skeletal | eqtl | 5.9e-03 | +0.10 | 16:66362238:C:T |
| Brain Nucleus accumbens basal ganglia | eqtl | 6.8e-03 | +0.22 | 16:67200231:A:G |
| Heart Atrial Appendage | eqtl | 9.6e-03 | +0.19 | 16:66893016:C:T |
| Skin Sun Exposed Lower leg | sqtl | 1.1e-02 | +0.48 | 16:67178129:GAGCCCCGCCCCTCGCCCGA:G |
| Artery Tibial | sqtl | 1.2e-02 | -0.88 | 16:67176952:G:C |
| Whole Blood | eqtl | 1.4e-02 | +0.44 | 16:66325258:C:T |
| Cells Cultured fibroblasts | eqtl | 1.8e-02 | +0.16 | 16:67238474:T:C |
FANTOM5 promoters
5 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 157747 | 19.2620 | 1774 |
| 157745 | 2.9066 | 1211 |
| 157744 | 1.0242 | 403 |
| 157743 | 0.4315 | 96 |
| 157746 | 0.0599 | 16 |
Top tissues by expression
showing 100 of 244 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right hemisphere of cerebellum | UBERON:0014890 | 98.60 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 98.45 | gold quality |
| cerebellar cortex | UBERON:0002129 | 98.40 | gold quality |
| cerebellum | UBERON:0002037 | 97.84 | gold quality |
| cortical plate | UBERON:0005343 | 97.18 | gold quality |
| adenohypophysis | UBERON:0002196 | 97.05 | gold quality |
| right ovary | UBERON:0002118 | 96.40 | gold quality |
| left ovary | UBERON:0002119 | 96.26 | gold quality |
| pituitary gland | UBERON:0000007 | 96.25 | gold quality |
| right adrenal gland | UBERON:0001233 | 95.35 | gold quality |
| right uterine tube | UBERON:0001302 | 95.34 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 95.29 | gold quality |
| left uterine tube | UBERON:0001303 | 95.17 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 94.83 | gold quality |
| embryo | UBERON:0000922 | 94.49 | gold quality |
| ganglionic eminence | UBERON:0004023 | 94.49 | gold quality |
| right frontal lobe | UBERON:0002810 | 94.43 | gold quality |
| left adrenal gland | UBERON:0001234 | 94.27 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 94.17 | gold quality |
| adrenal cortex | UBERON:0001235 | 93.52 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 93.39 | gold quality |
| right testis | UBERON:0004534 | 93.33 | gold quality |
| left testis | UBERON:0004533 | 92.77 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 92.75 | gold quality |
| endocervix | UBERON:0000458 | 92.64 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 92.57 | gold quality |
| body of uterus | UBERON:0009853 | 92.51 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 92.24 | gold quality |
| mucosa of stomach | UBERON:0001199 | 92.21 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 92.21 | gold quality |
| lower esophagus | UBERON:0013473 | 92.20 | gold quality |
| thyroid gland | UBERON:0002046 | 91.98 | gold quality |
| metanephros cortex | UBERON:0010533 | 91.98 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 91.60 | gold quality |
| apex of heart | UBERON:0002098 | 91.53 | gold quality |
| adrenal gland | UBERON:0002369 | 91.46 | gold quality |
| ectocervix | UBERON:0012249 | 91.11 | gold quality |
| hypothalamus | UBERON:0001898 | 90.79 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 90.65 | gold quality |
| ovary | UBERON:0000992 | 90.47 | gold quality |
| body of stomach | UBERON:0001161 | 90.43 | gold quality |
| amygdala | UBERON:0001876 | 90.26 | gold quality |
| omental fat pad | UBERON:0010414 | 90.22 | gold quality |
| testis | UBERON:0000473 | 90.21 | gold quality |
| peritoneum | UBERON:0002358 | 90.16 | gold quality |
| nucleus accumbens | UBERON:0001882 | 90.10 | gold quality |
| caudate nucleus | UBERON:0001873 | 89.86 | gold quality |
| neocortex | UBERON:0001950 | 89.83 | gold quality |
| brain | UBERON:0000955 | 89.45 | gold quality |
| prefrontal cortex | UBERON:0000451 | 89.38 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 89.36 | gold quality |
| esophagus | UBERON:0001043 | 89.24 | gold quality |
| transverse colon | UBERON:0001157 | 89.22 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 89.19 | gold quality |
| right atrium auricular region | UBERON:0006631 | 89.07 | gold quality |
| frontal cortex | UBERON:0001870 | 89.05 | gold quality |
| forebrain | UBERON:0001890 | 88.85 | gold quality |
| stromal cell of endometrium | CL:0002255 | 88.81 | gold quality |
| putamen | UBERON:0001874 | 88.60 | gold quality |
| cerebral cortex | UBERON:0000956 | 88.59 | gold quality |
| primary visual cortex | UBERON:0002436 | 88.59 | gold quality |
| adipose tissue of abdominal region | UBERON:0007808 | 88.50 | gold quality |
| cardiac atrium | UBERON:0002081 | 88.45 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 88.43 | gold quality |
| spleen | UBERON:0002106 | 88.27 | gold quality |
| cortex of kidney | UBERON:0001225 | 88.23 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 88.19 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 88.02 | gold quality |
| uterine cervix | UBERON:0000002 | 87.93 | gold quality |
| left coronary artery | UBERON:0001626 | 87.86 | gold quality |
| stomach | UBERON:0000945 | 87.58 | gold quality |
| minor salivary gland | UBERON:0001830 | 87.49 | gold quality |
| cerebellar vermis | UBERON:0004720 | 87.48 | silver quality |
| spinal cord | UBERON:0002240 | 87.47 | gold quality |
| esophagus mucosa | UBERON:0002469 | 87.04 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 86.95 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 86.68 | gold quality |
| coronary artery | UBERON:0001621 | 86.52 | gold quality |
| fundus of stomach | UBERON:0001160 | 86.51 | gold quality |
| upper lobe of lung | UBERON:0008948 | 86.50 | gold quality |
| vagina | UBERON:0000996 | 86.44 | gold quality |
| Ammon’s horn | UBERON:0001954 | 86.44 | gold quality |
| gall bladder | UBERON:0002110 | 86.38 | gold quality |
| body of pancreas | UBERON:0001150 | 86.18 | gold quality |
| colonic epithelium | UBERON:0000397 | 86.07 | gold quality |
| small intestine | UBERON:0002108 | 85.99 | gold quality |
| prostate gland | UBERON:0002367 | 85.85 | gold quality |
| right lobe of liver | UBERON:0001114 | 85.79 | gold quality |
| right lung | UBERON:0002167 | 85.52 | gold quality |
| right coronary artery | UBERON:0001625 | 85.49 | gold quality |
| ventricular zone | UBERON:0003053 | 85.25 | gold quality |
| skin of abdomen | UBERON:0001416 | 85.24 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 85.13 | gold quality |
| ascending aorta | UBERON:0001496 | 85.11 | gold quality |
| endothelial cell | CL:0000115 | 85.07 | silver quality |
| temporal lobe | UBERON:0001871 | 85.04 | gold quality |
| thoracic aorta | UBERON:0001515 | 85.02 | gold quality |
| metanephros | UBERON:0000081 | 84.94 | gold quality |
| heart left ventricle | UBERON:0002084 | 84.75 | gold quality |
| fallopian tube | UBERON:0003889 | 84.61 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 4.18 |
HPA expression
RNA tissue specificity: Tissue enhanced
showing 60 of 80 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Pituitary gland | tissue | 42.4 | |
| Retina | tissue | 27.1 | |
| Postcentral gyrus | tissue | 24.2 | |
| Hippocampus | tissue | 22.3 | medium |
| Locus coeruleus | tissue | 18.4 | |
| Nucleus accumbens | tissue | 17.5 | |
| Frontal cortex | tissue | 15.2 | |
| Cerebellum | tissue | 13.8 | low |
| Vagina | tissue | 12.1 | low |
| Adrenal gland | tissue | 11.7 | high |
| Prefrontal cortex | tissue | 11.6 | |
| Cerebral cortex | tissue | 11.6 | high |
| Hippocampal formation | tissue | 11.2 | |
| Entorhinal cortex | tissue | 11.2 | |
| Olfactory bulb | tissue | 11.1 | |
| Temporal cortex | tissue | 11.1 | |
| Insular cortex | tissue | 11.0 | |
| Retrosplenial and cingulate cortex | tissue | 10.9 | |
| Motor cortex | tissue | 10.8 | |
| Somatosensory cortex | tissue | 10.6 | |
| Retrosplenial cortex | tissue | 10.6 | |
| Amygdala | tissue | 10.0 | |
| Occipital cortex | tissue | 10.0 | |
| Choroid plexus | tissue | 9.8 | |
| Ovary | tissue | 9.4 | medium |
| Endometrium 1 | tissue | 8.8 | high |
| Caudate putamen | tissue | 8.7 | |
| Fallopian tube | tissue | 8.3 | high |
| Basal ganglia | tissue | 8.2 | low |
| Corpus callosum | tissue | 8.1 | |
| Ventral forebrain | tissue | 8.1 | |
| Hypothalamus | tissue | 7.9 | |
| Thalamus | tissue | 7.7 | |
| Septum | tissue | 7.7 | |
| Stomach 1 | tissue | 7.6 | medium |
| Pons | tissue | 7.6 | |
| Midbrain | tissue | 7.5 | |
| Testis | tissue | 7.4 | high |
| Superior colliculi | tissue | 7.3 | |
| Epididymis | tissue | 7.1 | medium |
| Periaqueductal gray | tissue | 7.1 | |
| Spinal cord | tissue | 7.0 | |
| Substantia nigra | tissue | 6.8 | |
| Spleen | tissue | 6.7 | high |
| Smooth muscle | tissue | 6.6 | low |
| Medulla oblongata | tissue | 6.5 | |
| Parathyroid gland | tissue | 6.2 | high |
| Putamen | tissue | 6.2 | |
| Duodenum | tissue | 6.2 | high |
| Skin 1 | tissue | 5.9 | medium |
| Prostate | tissue | 5.7 | medium |
| Gallbladder | tissue | 5.6 | high |
| Adipose tissue | tissue | 5.5 | low |
| Placenta | tissue | 5.4 | medium |
| Small intestine | tissue | 5.3 | medium |
| Salivary gland | tissue | 4.9 | medium |
| Rectum | tissue | 4.9 | high |
| Lung | tissue | 4.9 | low |
| Appendix | tissue | 4.7 | high |
| Thyroid gland | tissue | 4.5 | medium |
Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Vermis (36.6), Flocculonodular lobe (36.2), Cerebellar cortex (32.0), Precentral gyrus (30.3), Ventral periolivary nuclei (28.2).
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
Targeting MATCAP1 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 51 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6867-5P | 100.00 | 82.21 | 3464 |
| HSA-MIR-5193 | 100.00 | 67.26 | 1744 |
| HSA-MIR-3646 | 100.00 | 73.56 | 5283 |
| HSA-MIR-4481 | 100.00 | 66.42 | 1669 |
| HSA-MIR-4682 | 100.00 | 68.89 | 1258 |
| HSA-MIR-29A-3P | 100.00 | 73.11 | 1835 |
| HSA-MIR-29B-3P | 100.00 | 73.18 | 1833 |
| HSA-MIR-29C-3P | 100.00 | 73.15 | 1833 |
| HSA-MIR-5692B | 100.00 | 71.32 | 2622 |
| HSA-MIR-5692C | 100.00 | 71.32 | 2622 |
| HSA-MIR-4745-5P | 99.98 | 65.95 | 1028 |
| HSA-MIR-374A-5P | 99.90 | 71.34 | 2923 |
| HSA-MIR-4302 | 99.89 | 67.94 | 1187 |
| HSA-MIR-3663-3P | 99.84 | 70.39 | 798 |
| HSA-MIR-4668-5P | 99.79 | 70.58 | 3782 |
| HSA-MIR-8076 | 99.78 | 68.52 | 1170 |
| HSA-MIR-4306 | 99.72 | 70.50 | 3630 |
| HSA-MIR-1296-3P | 99.72 | 64.04 | 636 |
| HSA-MIR-1284 | 99.67 | 73.56 | 1353 |
| HSA-MIR-452-5P | 99.65 | 69.63 | 1762 |
| HSA-MIR-4676-3P | 99.65 | 69.31 | 1733 |
| HSA-MIR-892C-3P | 99.65 | 69.38 | 1745 |
| HSA-MIR-4753-5P | 99.54 | 68.51 | 1356 |
| HSA-MIR-4696 | 99.48 | 67.48 | 1040 |
| HSA-MIR-3612 | 99.45 | 66.02 | 1333 |
| HSA-MIR-650 | 99.45 | 65.77 | 1309 |
| HSA-MIR-190B-3P | 99.33 | 68.29 | 1382 |
| HSA-MIR-7515 | 99.31 | 68.22 | 1795 |
| HSA-MIR-3164 | 99.02 | 68.39 | 1071 |
| HSA-MIR-6820-3P | 99.02 | 68.50 | 1035 |
Functional genomics
gnomAD constraint: pLI 2.31e-07, LOEUF 0.967, missense Z 1.23 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD)
ENST00000563902 splits into 3 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD
| Region (GRCh38) | Missense obs / exp | o/e | Constrained |
|---|---|---|---|
| 16:67,176,814–67,178,085 | 76 / 113.3 | 0.67 | no |
| 16:67,178,086–67,178,421 | 131 / 118.5 | 1.11 | no |
| 16:67,178,422–67,180,610 | 323 / 421.7 | 0.77 | no |
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | kiaa0895l | ENSDARG00000059529 |
| mus_musculus | Matcap1 | ENSMUSG00000014837 |
| rattus_norvegicus | Matcap1 | ENSRNOG00000015625 |
Paralogs (1): MATCAP2 (ENSG00000164542)
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:1921606) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 3 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| decreased brain size | 1 |
| small cerebellum | 1 |
| small olfactory bulb | 1 |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| EXOC3L1 | protein-coding | 283849 |
| HSF4 | protein-coding | 3299 |
| FBXL8 | protein-coding | 55336 |
| TRADD | protein-coding | 8717 |
| NOL3 | protein-coding | 8996 |
| PHAF1 | protein-coding | 80262 |
| B3GNT9 | protein-coding | 84752 |
| CBFB | protein-coding | 865 |
| E2F4 | protein-coding | 1874 |
| MIR328 | ncRNA | 442901 |
| ELMO3 | protein-coding | 79767 |
Protein
Protein identifiers
Microtubule-associated tyrosine carboxypeptidase 1 — Q68EN5 (reviewed: Q68EN5)
Alternative names: Microtubule-associated tyrosine carboxypeptidase
All UniProt accessions (2): Q68EN5, I3L230
UniProt curated annotations — full annotation on UniProt →
Function. Tyrosine carboxypeptidase that removes the C-terminal tyrosine residue of alpha-tubulin, thereby regulating microtubule dynamics and function. Also able to remove the C-terminal phenylalanine residue of alpha-tubulin TUBA8. Recognizes adjacent tubulin dimers along the same protofilament.
Subcellular location. Cytoplasm. Cytoskeleton.
Cofactor. Binds 1 zinc ion per subunit.
Domain organisation. Metalloprotease with an atypical HExxxH zinc-binding motif instead of HExxH, which interrupts the active site-containing helix without affecting the integrity of the catalytic site arrangement. The N-terminal disordered region enhances its anchoring on microtubules, while dampening processivity on the polymerized substrate.
Similarity. Belongs to the peptidase MATCAP family.
Isoforms (3)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q68EN5-1 | 1 | yes |
| Q68EN5-2 | 2 | |
| Q68EN5-3 | 3 |
RefSeq proteins (8): NP_001035805, NP_001356609, NP_001356610, NP_001356611, NP_001356613, NP_001356614, NP_001356615, NP_001356616 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR012548 | MATCAP | Family |
Pfam: PF08014
Catalyzed reactions (Rhea)
- C-terminal L-alpha-aminoacyl-L-glutamyl-L-glutamyl-L-tyrosyl-[tubulin] + H2O = C-terminal L-alpha-aminoacyl-L-glutamyl-L-glutamyl-[tubulin] + L-tyrosine (RHEA:57444)
- C-terminal L-alpha-aminoacyl-L-glutamyl-L-glutamyl-L-phenylalanyl-[tubulin] + H2O = C-terminal L-alpha-aminoacyl-L-glutamyl-L-glutamyl-[tubulin] + L-phenylalanine (RHEA:72663)
UniProt features (52 total): helix 26, mutagenesis site 7, turn 5, strand 4, binding site 3, splice variant 3, region of interest 2, chain 1, active site 1
Structure
Experimental structures (PDB)
3 structures by resolution:
| PDB | Title | Method | Resolution (Å) |
|---|---|---|---|
| 7Z5G | human apo MATCAP | X-RAY DIFFRACTION | 2.11 |
| 7Z5H | human Zn MATCAP | X-RAY DIFFRACTION | 2.5 |
| 7Z6S | MATCAP bound to a human 14 protofilament microtubule | ELECTRON MICROSCOPY | 2.9 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q68EN5-F1 | 77.94 | 0.65 |
Human Protein Atlas
Protein class: Enzymes, ENZYME proteins, Hydrolases, Peptidases, Threonine-type peptidases, Predicted intracellular proteins
Protein evidence: Evidence at protein level
Subcellular location (HPA, imaging): nucleoplasm; vesicles
Antibody reliability (HPA): IH approved · IF approved
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (1)
| Position | Role |
|---|---|
| 281 | nucleophile |
Ligand- & substrate-binding residues (3)
| Position | Role |
|---|---|
| 280 | Zn(2+) |
| 285 | Zn(2+) |
| 316 | Zn(2+) |
Mutagenesis-validated functional residues (7)
| Position | Phenotype |
|---|---|
| 219 | reduced binding to microtubules. |
| 223 | reduced binding to microtubules. |
| 227 | reduced binding to microtubules. |
| 280 | abolished tyrosine carboxypeptidase activity. |
| 281 | abolished tyrosine carboxypeptidase activity. |
| 285 | abolished tyrosine carboxypeptidase activity. |
| 316 | abolished tyrosine carboxypeptidase activity. |
Function
Pathways and Gene Ontology
Reactome pathways
0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
MSigDB gene sets: 67 (showing top):
chr16q22, GOMF_METALLOPEPTIDASE_ACTIVITY, GOBP_HEAD_DEVELOPMENT, GOBP_PROTEOLYSIS, GOMF_CARBOXYPEPTIDASE_ACTIVITY, GOMF_METALLOEXOPEPTIDASE_ACTIVITY, GOMF_METALLOCARBOXYPEPTIDASE_ACTIVITY, GOMF_PEPTIDASE_ACTIVITY, GOMF_EXOPEPTIDASE_ACTIVITY, KAMMINGA_SENESCENCE, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A, GOCC_SUPRAMOLECULAR_COMPLEX, GOCC_POLYMERIC_CYTOSKELETAL_FIBER, GOCC_SUPRAMOLECULAR_POLYMER, ASH1L_TARGET_GENES
GO Biological Process (2): proteolysis (GO:0006508), brain development (GO:0007420)
GO Molecular Function (7): metallocarboxypeptidase activity (GO:0004181), tubulin-tyrosine carboxypeptidase activity (GO:0106423), carboxypeptidase activity (GO:0004180), protein binding (GO:0005515), peptidase activity (GO:0008233), metallopeptidase activity (GO:0008237), hydrolase activity (GO:0016787)
GO Cellular Component (2): microtubule (GO:0005874), cytoskeleton (GO:0005856)
GO top-level categories
16 GO namespaces:
| Category | Terms |
|---|---|
| protein metabolic process | 1 |
| central nervous system development | 1 |
| animal organ development | 1 |
| head development | 1 |
| carboxypeptidase activity | 1 |
| metalloexopeptidase activity | 1 |
| metallocarboxypeptidase activity | 1 |
| exopeptidase activity | 1 |
| binding | 1 |
| hydrolase activity | 1 |
| catalytic activity, acting on a protein | 1 |
| peptidase activity | 1 |
| catalytic activity | 1 |
| microtubule cytoskeleton | 1 |
| polymeric cytoskeletal fiber | 1 |
| intracellular membraneless organelle | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 3 of 11 annotations. The rest are phylogenetic / computational / electronic (IEA).
3 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| microtubule | CC | direct assay |
| metallocarboxypeptidase activity | MF | direct assay |
| tubulin-tyrosine carboxypeptidase activity | MF | direct assay |
Protein interactions and networks
STRING
showing 15 of 176 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| MATCAP1 | ESPNL | Q6ZVH7 | 566 |
| MATCAP1 | SVBP | Q8N300 | 529 |
| MATCAP1 | GABPB1 | Q06547 | 461 |
| MATCAP1 | VASH2 | Q86V25 | 432 |
| MATCAP1 | EXOC3L1 | Q86VI1 | 418 |
| MATCAP1 | Q8WV35 | Q8WV35 | 418 |
| MATCAP1 | ATG16L2 | Q8NAA4 | 413 |
| MATCAP1 | VASH1 | Q7L8A9 | 400 |
| MATCAP1 | ATG4D | Q86TL0 | 391 |
| MATCAP1 | PITHD1 | Q9GZP4 | 390 |
| MATCAP1 | B3GNT9 | Q6UX72 | 390 |
| MATCAP1 | RIMS2 | Q9UQ26 | 368 |
| MATCAP1 | TMEM208 | Q9BTX3 | 358 |
| MATCAP1 | FBXL8 | Q96CD0 | 349 |
| MATCAP1 | TTLL2 | Q9BWV7 | 348 |
IntAct
Human interaction partners of MATCAP1 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
1 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| ZBTB8B | physical association | 0.560 | 3 |
Disease & clinical
Genetic variants
Variant evidence for MATCAP1: 81 ClinVar records (0 pathogenic / likely pathogenic); 2 GWAS associations.
ClinVar
81 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 73 |
| Likely benign | 1 |
| Benign | 0 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 26 predictions of 1,033):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 16:67176976 | acceptor_loss | 1.0000 | |
| 16:67178008–67178009 | donor_loss | 1.0000 | 5 |
| 16:67178013 | donor_gain | 1.0000 | |
| 16:67178108–67178109 | acceptor_loss | 1.0000 | 6 |
| 16:67178843 | donor_gain | 1.0000 | |
| 16:67176976–67176977 | acceptor_loss | 0.9900 | 2 |
| 16:67176980 | acceptor_gain | 0.9900 | |
| 16:67178180 | donor_gain | 0.9900 | |
| 16:67178197–67178198 | donor_loss | 0.9900 | 3 |
| 16:67178505–67178506 | acceptor_loss | 0.9900 | 5 |
AlphaMissense
1,199 missense substitutions predicted likely pathogenic (of 3,027 scored), across 272 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| M253 | 9 | 0.957 | 0.998 |
| M277 | 9 | 0.889 | 0.991 |
| H280 | 8 | 0.999 | 1.000 |
| H285 | 8 | 0.999 | 1.000 |
| D390 | 8 | 0.998 | 0.999 |
| F440 | 8 | 0.983 | 0.999 |
| F166 | 8 | 0.981 | 0.998 |
| F350 | 8 | 0.979 | 0.996 |
| N291 | 8 | 0.974 | 0.999 |
| N458 | 8 | 0.974 | 0.999 |
| H322 | 8 | 0.971 | 0.999 |
| F387 | 8 | 0.968 | 0.997 |
| F409 | 8 | 0.967 | 0.998 |
| D422 | 8 | 0.963 | 0.985 |
| F208 | 8 | 0.955 | 0.996 |
| F155 | 8 | 0.953 | 0.997 |
| S323 | 8 | 0.949 | 1.000 |
| N312 | 8 | 0.947 | 0.997 |
| S320 | 8 | 0.903 | 1.000 |
| D395 | 8 | 0.745 | 0.892 |
HPA cancer prognostics
RNA cancer specificity: Low cancer specificity
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
3 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Kidney Renal Papillary Cell Carcinoma (TCGA) | favorable | 0.000185 |
| Colon Adenocarcinoma (TCGA) | unfavorable | 0.000428 |
| Liver Hepatocellular Carcinoma (validation) | favorable | 0.000681 |
Disease associations
OMIM: gene MIM:619978 | disease phenotypes:
GWAS associations
2 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST006979_877 | Heel bone mineral density | 1e-27 |
| GCST004602_183 | Mean corpuscular volume | 2e-16 |
EFO canonical traits (from GWAS)
1 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0009270 | heel bone mineral density |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (CPIC guideline: no)
CTD chemical–gene interactions
13 total (human), top 13 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Tobacco Smoke Pollution | decreases expression | 2 |
| sulforaphane | decreases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| benzo(e)pyrene | decreases methylation | 1 |
| abrine | increases expression | 1 |
| Sunitinib | decreases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Doxorubicin | decreases expression | 1 |
| Methapyrilene | decreases methylation | 1 |
| Quercetin | increases expression | 1 |
| Valproic Acid | increases methylation | 1 |
| Okadaic Acid | increases expression | 1 |
| Acrylamide | decreases expression | 1 |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.